A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Subjects with ESRD treated with hemodialysis 3 times a week for at least 3 months
prior enrollment.

- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to
the start of study treatment.

- Women must not be breastfeeding

- Women of childbearing potential (WOCBP) must agree to follow instructions for
method(s) of contraception for the duration of treatment with study treatment(s)
BMS-986177 plus 5 half-lives of study treatment (2 days) plus 30 days (duration of
ovulatory cycle) for a total of 32 days post-treatment completion

- Males who are sexually active with WOCBP must agree to follow instructions for
method(s) of contraception for the duration of treatment with study treatment(s)
BMS-986177 plus 5 half-lives of the study treatment plus 90 days (duration of sperm
turnover) for a total of 92 days post-treatment completion. In addition, male
participants must be willing to refrain from sperm donation during this time.

Exclusion Criteria:

- Subjects receiving dialysis through central venous catheters

- History of uncontrolled or unstable cardiovascular, respiratory, hepatic,
gastrointestinal, endocrine, hematopoietic, psychiatric and/or neurological disease in
the past 3 months

- Current or recent (within 3 months of study drug administration) gastrointestinal
disease or surgery, which by the judgment of the Investigator, may increase a
subject's risk of gastrointestinal bleeding or interfere with absorption of study drug
(e.g., peptic or gastric ulcer disease, severe gastritis, history of gastrointestinal
surgery).

- Any major surgery within 12 weeks of study drug administration

- History of significant head injury within the last 2 years, including subjects with
base of skull fractures

Other protocol defined inclusion/exclusion criteria could apply